84 related articles for article (PubMed ID: 12544310)
1. Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia.
Sherwood JB; McConnell JD; Vazquez DJ; Lin VK; Roehrborn CG
J Urol; 2003 Feb; 169(2):575-9. PubMed ID: 12544310
[TBL] [Abstract][Full Text] [Related]
2. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
3. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH).
Rennie PS; Bruchovsky N; McLoughlin MG; Batzold FH; Dunstan-Adams EE
J Steroid Biochem; 1983 Jul; 19(1A):169-73. PubMed ID: 6193340
[TBL] [Abstract][Full Text] [Related]
5. [Is a single prostatic biopsy sufficient for selection of medical treatment in benign prostatic hypertrophy?].
Zlotta AR; Sattar AA; Wespes E; Haot J; Schulman CC
Acta Urol Belg; 1995 Mar; 63(1):83-7. PubMed ID: 7537013
[TBL] [Abstract][Full Text] [Related]
6. Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue.
Shirakawa T; Okada H; Acharya B; Zhang Z; Hinata N; Wada Y; Uji T; Kamidono S; Gotoh A
Prostate; 2004 Jan; 58(1):33-40. PubMed ID: 14673950
[TBL] [Abstract][Full Text] [Related]
7. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
[TBL] [Abstract][Full Text] [Related]
8. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
Neves AF; Araújo TG; Biase WK; Meola J; Alcântara TM; Freitas DG; Goulart LR
Clin Biochem; 2008 Oct; 41(14-15):1191-8. PubMed ID: 18640109
[TBL] [Abstract][Full Text] [Related]
10. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate.
Tiniakos DG; Mitropoulos D; Kyroudi-Voulgari A; Soura K; Kittas C
Urology; 2006 Jan; 67(1):204-8. PubMed ID: 16413376
[TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of steroid 5alpha-reductase isoenzymes in benign hyperplastic prostate tissues].
Ye LF; Zhang YF; Fang ZJ; Ding Q; Yao MS
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1296-9. PubMed ID: 12930680
[TBL] [Abstract][Full Text] [Related]
14. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
15. Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
Byun SS; Jeong H; Jo MK; Lee E
Urology; 2005 Sep; 66(3):593-6. PubMed ID: 16140084
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
[TBL] [Abstract][Full Text] [Related]
17. Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues.
Oliveira OL; Koff WJ; Muraro F; Santos EB; Gomes Soares DF; Trindade VM
Clin Chim Acta; 2008 May; 391(1-2):36-40. PubMed ID: 18328817
[TBL] [Abstract][Full Text] [Related]
18. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.
Nichol MB; Knight TK; Wu J; Barron R; Penson DF
J Urol; 2009 May; 181(5):2214-21; discussion 2221-2. PubMed ID: 19296986
[TBL] [Abstract][Full Text] [Related]
19. Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia.
Angelucci C; Iacopino F; Lama G; Zelano G; Gianesini G; Sica G; Bono AV
Anticancer Res; 2005; 25(6B):3937-41. PubMed ID: 16309180
[TBL] [Abstract][Full Text] [Related]
20. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
